The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACR, ASCO and SNM) and in January (post SMI, ISOQOL, ASTRO, RSNA and ASH) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention. This pilot issue includes the 2007 ASCO Annual Meeting and GI Cancers Symposium and Cancer Therapy Evaluation Program activities.

Research Highlights in this Issue:

Addition of two courses of arsenic trioxide consolidation following remission induction significantly improves event-free survival in acute promyelocytic leukemia (APL). Abstract 2 (Leukemia, Myelodysplasia, and Transplantation/CALGB/Powell et al.)

Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary GIST. Abstract 10079 (Gastrointestinal Cancer/ACOSOG/DeMatteo et al.)
Cooperative Group Abstracts

Breast Cancer

**CALGB**


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/1009](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/1009)

Protocol(s): CALGB-9480, CALGB-150002

**ECOG**


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/21022](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/21022)

Protocol(s): E2197


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/526](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/526)

Protocol(s): E2197


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/596](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/596)

Protocol(s): E2190


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/1033](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/1033)

Protocol(s): E1100


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/516](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/516)

Protocol(s): E1199
Protocol(s): E1103

NCCTG

Protocol(s): N9831

Protocol(s): N0531

NCIC Clinical Trials Group

Protocol(s): NCIC-MA.21

Protocol(s): JMA17

NSABP

Protocol(s): NSABP-B-07, NSABP-B-22, NSABP-B-08, NSABP-B-16, NSABP-B-15, NSABP-B-12, NSABP-B-09, NSABP-B-05, NSABP-B-10, NSABP-B-28, NSABP-B-25, NSABP-B-31, NSABP-B-11
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/511
Protocol(s): NSABP-B-31

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/512
Protocol(s): N9831, NSABP-B-31

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/LBA513
Protocol(s): NSABP-B-31

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/529
Protocol(s): NSABP-B-20

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/520
Protocol(s): NSABP-B-24, NSABP-B-17

SWOG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/11051
Protocol(s): S0012

CNS Cancer

NCCTG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2004
Protocol(s): N047B
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2075  
Protocol(s): Multiple Trials

Gastrointestinal Cancer

ACOSOG

Protocol(s): ACOSOG-Z9001

CALGB

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4508  
Protocol(s): CALGB-80303

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4019  
Protocol(s): C89803

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9008  
Protocol(s): CALGB-80303

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4067  
Protocol(s): N9741
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4524  
Protocol(s): CALGB-80303

**ECOG**

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4519  
Protocol(s): E8200

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4100  
Protocol(s): E3200

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4533  
Protocol(s): E1201

**NCCTG**

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4057  
Protocol(s): N9741

Protocol(s): N9943
Protocol(s): N044J

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4080
Protocol(s): N9741

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4011
Protocol(s): Multiple Trials

Protocol(s): N0349

Protocol(s): N034A

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4553
Protocol(s): N034A

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4578
Protocol(s): N9943

Protocol(s): NSABP-C-07, NSABP-C-05, NSABP-C-03, NSABP-C-06, NSABP-C-04, NSABP-C-02, NSABP-C-01
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4008
Protocol(s): NSABP-C-07, NSABP-C-03, NSABP-C-01, NSABP-C-02, NSABP-C-05, NSABP-C-04, NSABP-C-06

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4017
Protocol(s): NSABP-C-04, NSABP-C-01, NSABP-C-07, NSABP-C-05, NSABP-C-06, NSABP-C-02, NSABP-C-03

**NSABP**

Protocol(s): NSABP-C-07, NSABP-C-06, NSABP-C-04, NSABP-C-02, NSABP-C-01, NSABP-C-05, NSABP-C-03

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4008
Protocol(s): NSABP-C-07, NSABP-C-02, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-03, NSABP-C-01

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4017
Protocol(s): NSABP-C-07, NSABP-C-02, NSABP-C-06, NSABP-C-03, NSABP-C-04, NSABP-C-05, NSABP-C-01

**RTOG**

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1CRD&vmview=abst_detail_view&confID=47&abstractID=31938
Protocol(s): RTOG-97-04
[http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=33400](http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=33400)
Protocol(s): RTOG-97-04

[http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=46&abstractID=20241](http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=46&abstractID=20241)
Protocol(s): RTOG-85-31

[http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=45&abstractID=10252](http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=45&abstractID=10252)
Protocol(s): RTOG-92-08

[http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=31494](http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=31494)
Protocol(s): RTOG-0315

**SWOG**

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4647](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4647)
Protocol(s): S0413

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4639](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4639)
Protocol(s): S0514

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4621](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4621)
Protocol(s): S0413

Protocol(s): S0205

Genitourinary Cancer

ECOG


Protocol(s): E4802


Protocol(s): E6800

NCCTG


Protocol(s): N00CB

RTOG


Protocol(s): RTOG-85-31


Protocol(s): RTOG-85-31
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310es37a01d/?vgnextoid=76f8201eb61a7010VgnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=46&abstractID=2013
Protocol(s): RTOG-94-06

SWOG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5108
Protocol(s): S0412

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/15516
Protocol(s): S0317

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/15562
Protocol(s): S0312

Gynecologic Cancer

GOG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/21021
Protocol(s): GOG-0218

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5521
Protocol(s): GOG-0172
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/21050
Protocol(s): GOG-0172

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5534
Protocol(s): GOG-0179, GOG-0169

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/16027
Protocol(s): GOG-0172

SWOG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5551
Protocol(s): S0200

Head and Neck Cancer

ECOG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6000
Protocol(s): E2399

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6015
Protocol(s): E2303
SWOG

Adelstein DJ, Moon J, Hanna E, Shankar Giri PG, Mills GM, Wolf GT and Urba SG: S0216: A Southwest Oncology Group (SWOG) phase II trial of docetaxel (T), cisplatin (P), and fluorouracil (F) induction followed by accelerated fractionation/concomitant boost (AF/CB) radiotherapy (RT) and concurrent cisplatin for advanced head and neck squamous cell cancer (HNSCC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.6014.
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6014
Protocol(s): S0216

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6044
Protocol(s): S0420

Leukemia, Myelodysplasia, and Transplantation

CALGB

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=33770
Protocol(s): CALGB-19808

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=30319
Protocol(s): CALGB-10201

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2
Protocol(s): C9710

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7010
Protocol(s): CALGB-19808
Protocol(s): C9710

Protocol(s): CALGB-9665, CALGB-19808, CALGB-8461

COG

Protocol(s): P9407

Protocol(s): CCG-1991

Protocol(s): ADVL04P2

Protocol(s): C9710
Lymphoma and Plasma Cell Disorders

**CALGB**


Protocol(s): E4494

**ECOG**


Protocol(s): E4494


Protocol(s): E1496


Protocol(s): E4494


Protocol(s): E4A03

Lung Cancer

**ACOSOG**


Protocol(s): NCCTG-97-24-51, ACOSOG-Z9001
**CALGB**

Green MR, Miller AA, Wang X, Gu L, Vokes EE: Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC): CAL. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7617.

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7617](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7617)

Protocol(s): CALGB-30303


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7565](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7565)

Protocol(s): CALGB-30206


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7595](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7595)

Protocol(s): CALGB-30402


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7563](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7563)

Protocol(s): CALGB-30306

**ECOG**


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7588](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7588)

Protocol(s): E3503


[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7535](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7535)

Protocol(s): E4599
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7564
Protocol(s): E3501

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7508
Protocol(s): E3503

NCCTG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7547
Protocol(s): N0326

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7723
Protocol(s): Multiple Trials

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6511
Protocol(s): NCCTG-97-24-51, ACOSOG-Z9001

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8565
Protocol(s): N0071

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/19503
Protocol(s): NCCTG-90-24-51


http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=31584
Protocol(s): RTOG-0239


http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=34110
Protocol(s): RTOG-02-70


http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=30511
Protocol(s): RTOG-98-01

SWOG


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7549
Protocol(s): S0023, S0342, S0341


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7500
Protocol(s): S0003


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7545
Protocol(s): S0342
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7536  
Protocol(s): S0341

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7513  
Protocol(s): S0023

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7524  
Protocol(s): S0124

**Melanoma/Skin Cancers**

**ECOG**

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/8506  
Protocol(s): E2696

**NCCTG**

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8560  
Protocol(s): N047A

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/8530  
Protocol(s): N0377
Sarcoma/Bone and Soft Tissue Cancers

**COG**

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/10011](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/10011)  
Protocol(s): INT0091

**ECOG**

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/20503](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/20503)  
Protocol(s): E1D96

**SWOG**

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/10004](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/10004)  
Protocol(s): S0033

Other Cancer

**CALGB**

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/3538](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/3538)  
Protocol(s): CALGB-60301

**COG**

[http://meeting.jco.org/cgi/content/abstract/25/18_suppl/14094](http://meeting.jco.org/cgi/content/abstract/25/18_suppl/14094)  
Protocol(s): ADVL0516
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9504
Protocol(s): A3961

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9569
Protocol(s): ADVL0416

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9505
Protocol(s): A3973

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9546
Protocol(s): ADVL0415

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9563
Protocol(s): ADVL0414

ECOG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5051
Protocol(s): EST-3887, EST-4887

NCCTG

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9001
Protocol(s): N03CA

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9021

Protocol(s): Multiple Trials

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators


http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/6632


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/14094


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6533


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9569


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2004


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9565


http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9546
http://meeting.jco.org/cgi/content/abstract/25/18_suppl/3575

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5537

DCTD and DCP Activities

Scientific


Dr. E. Trimble (DCTD/CTEP): Coordinator and NCI member, Gynecologic Cancer Steering Committee (GCSC) meeting. American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007.


Educational


Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.